Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma
Status and phase
Completed
Phase 3
Conditions
Treatment of Bone Metastases
Treatments
Drug: Zoledronic acid
Details and patient eligibility
About
Zoledronic acid is a medication that slows the breakdown of bone. This study will assess the efficacy and safety of zoledronic acid in Chinese patients with multiple myeloma or other solid tumors with bone metastases.
Sex
All
Ages
18+ years old
Volunteers
No Healthy Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
- Cancer patients (multiple myeloma or other solid tumors) and confirmed evidence of bone lesions
- Significant bone pain
Exclusion Criteria
- Poor renal function
- Use of other investigational drugs within 30 days of visit 2
- Dental or other surgery to the jaw within 6 weeks of screening, or planned during the 4 week study
Other protocol-defined exclusion criteria may apply.
Trial design
Primary purpose
Treatment
Allocation
Randomized
Interventional model
Parallel Assignment
Masking
Double Blind
Trial contacts and locations
1
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems